News

"The case highlights a critical, albeit rare, side effect of lenvatinib in the treatment of VHL syndrome, pointing to the necessity of individualized treatment strategies, vigilant monitoring, and ...
Sex differences in kidney diseases have received limited attention. Research in this area is crucial for developing targeted ...
The authors study how apolipoprotein L1 variants impact inflammation and lipid accumulation in macrophages. The findings will be useful for researchers investigating macrophage metabolism and ...
The single mom is urgently seeking a kidney donor and has turned her car into a mobile plea, listing her blood type and contact info.
Learn about living organ donation and the importance of organ transplant awareness. Discover the process and benefits of ...
ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and ...
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th ...
Medical device steriliser Nanosonics is pushing for stronger sales of its flagship device Trophon, ahead of the release of an ... Read More The post Health Check: Amid headwinds, Nanosonics goes bells ...
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Focal and segmental glomerulosclerosis (FSGS) is the most common histologic pattern of renal injury seen in adults with idiopathic proteinuria.
Dimerix Limited has granted Amicus Therapeutics exclusive rights to commercialize its drug candidate DMX-200 in the U.S. for Focal Segmental Glomerulosclerosis (FSGS), a serious kidney disease ...
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) ...